bioMérieux SA

DUBLIN--( BUSINESS WIRE )--The "Monkeypox (MPOX) Diagnostics Global Markets 2024-2028, by Assay, by Country, by Product and by Place: Executive and Consultant Guides, Market Analysis and Forecasts" report has been added to ResearchAndMarkets.com's offering. Monkeypox is being declared a health emergency. Governments around the world are preparing to use widespread testing to get in front of this threat from the beginning. Opportunities abound for the In Vitro Diagnostic Industry. The report forecasts the market size out to 2028. Learn about this market including the issues and outlooks. The two key trends of Rapid Diagnostics and the Genomics Revolution are merging to create new diagnostic opportunities. Growth is coming from the basic factors but the COVID Pandemic has changed to market landscape now and for the foreseeable future. Some players have already made their mark but disruptive diagnostic technology could change the playing field. This research makes you the expert in your organization. Make investment decisions and valuations with confidence using the latest data. All report data is available in Excel format on request. Key Topics Covered: 1 Market Guides 1.1 Situation Analysis 1.2 Guide for Executives and Marketing Staff 1.3 Guide for Investment Analysts and Management Consultants 2 Introduction and Market Definition 2.1 An Overview of Monkeypox Diagnostics 2.1.1 The 2022 Outbreak 2.2 Market Definition 2.2.1 Market Size 2.2.2 Currency 2.2.3 Years 2.2.4 PCR 2.2.5 NGS 2.2.6 Immunoassay 2.2.7 Rapid Diagnostics 2.2.8 Limitations 2.3 Methodology 2.3.1 Methodology 2.3.2 Sources 2.3.3 Authors 2.4 Perspective: Healthcare and the IVD Industry 2.4.1 Global Healthcare Spending 2.4.2 Spending on Diagnostics 2.4.3 Important Role of Insurance for Diagnostics 3 Monkeypox - Current Science 3.1 What is Monkeypox? 3.2 Outbreaks 3.3 Transmission 3.4 Signs and symptoms 3.5 Diagnosis 3.6 Therapeutics 3.6.1 Vaccination 3.6.2 Prevention 3.6.2.1 Reducing the risk of human-to-human transmission 3.6.2.2 Reducing the risk of zoonotic transmission 3.7 How monkeypox relates to smallpox 4 Industry Overview 4.1 Players in a Dynamic Market 4.1.1 Academic Research Lab 4.1.2 Diagnostic Test Developer 4.1.3 Pharmaceutical/Reagent Supplier 4.1.4 Independent Testing Lab 4.1.5 Public National/regional lab 4.1.6 Hospital lab 4.1.7 Physician Lab 4.1.8 Audit Body 4.1.9 Certification Body 5 Market Trends 5.1 Factors Driving Growth 5.1.1 Prevalence 5.1.2 Surveillance 5.1.3 Pandemic Wind Down 5.1.4 Viral Zeitqeist 5.1.5 Healthcare Spend 5.2 Factors Limiting Growth 5.2.1 The Cost Curve Shrinks the Market 5.2.2 Transmission Outlook 5.2.3 Adoption Lag and Cost Control 5.3 Diagnostic Technology Development 5.3.1 The Multiplex Opportunity 5.3.2 Shifting Role of Physicians in Diagnosis 5.3.3 Diagnostics Moves Out of the Lab 5.3.4 Biomarkers and Algorithms 5.3.5 Rapid Testing Changing Medical Practice 5.3.6 Genome Role and Big Data 6 Mpox Diagnostics - Recent Developments 6.1 Recent Developments - Importance and How to Use This Section 6.1.1 Importance of These Developments 6.1.2 How to Use This Section 6.2 WHO Declares MPOX a Health Emergency 6.3 Human monkeypox disease prediction 6.4 Most Dangerous Monkeypox Virus Yet 6.5 South Africa reports second mpox death 6.6 New Strain of MPOX Raising Alarm 6.7 Labcorp Receives EUA for Home Mpox Test 6.8 Ultrasensitive single-step CRISPR detection of MPOX virus 6.9 Many new mpox cases are in China 6.10 U.S. to declare monkeypox a public health emergency 6.11 BioGX Gets CE-IVD Mark for Multigene POC Test 6.12 World Health Organization declares monkeypox a global emergency 6.13 Quest Begins Offering Internally Developed Monkeypox Test 6.14 CDC, Abbott, Roche, BioMerieux Get FDA 510(k) Clearances 6.15 Commercial, Academic Labs Ramp Up Monkeypox Testing 6.16 Becton Dickinson, CerTest Biotec Collaborate on Monkeypox MDx 6.17 Monkeypox Virus Sequenced 7 Profiles of Key Companies 7.1 Abbott Laboratories 7.2 Aegis Science Corporation 7.3 Applied DNA Sciences 7.4 Beckman Coulter Diagnostics (Danaher) 7.5 Becton, Dickinson and Company 7.6 BGI Genomics Co. Ltd 7.7 BioFire Diagnostics (bioMerieux) 7.8 BioGX 7.9 bioMerieux Diagnostics 7.10 Bio-Rad Laboratories, Inc. 7.11 Cepheid (Danaher) 7.12 Cerstest Biotec 7.13 Flow Health 7.14 Laboratory Corporation of America 7.15 Mayo Clinic Laboratories 7.16 Novacyt 7.17 Proof Diagnostics 7.18 Qiagen 7.19 Quest Diagnostics 7.20 Roche Diagnostics 7.21 Siemens Healthineers 7.22 Sonic Healthcare 7.23 Sysmex 7.24 Thermo Fisher Scientific 7.25 Vela Diagnostics 8 Monkeypox Global Diagnostic Markets Overview 8.1 Monkeypox Diagnostics - Global Market Overview by Country 8.2 Global Monkeypox Diagnostics Markets Overview by Assay 8.3 Global Monkeypox Diagnostics Markets Overview by Product 8.4 Global Monkeypox Diagnostics Markets Overview by Place 9 Monkeypox Diagnostic Market - by Assay 9.1 Monkeypox Diagnostic - PCR 9.2 Monkeypox Diagnostic - NGS 9.3 Monkeypox Diagnostic - Immunoassay 9.4 Monkeypox Diagnostic - Other Assay 10 Global Monkeypox Diagnostics Markets - By Product 10.1 Monkeypox Diagnostic - Instrumentation 10.2 Monkeypox Diagnostic - Consumables 10.3 Monkeypox Diagnostic - Software & Service 11 Global Monkeypox Diagnostics Markets - By Place 11.1 Monkeypox Diagnostic - Hospital 11.2 Monkeypox Diagnostic - Clinic/POL 11.3 Monkeypox Diagnostic - Other Place 12 Appendices 12.1 Commercially Available Monkeypox Tests 12.2 United States Medicare System: Clinical Laboratory Fees Schedule For more information about this report visit https://www.researchandmarkets.com/r/5a91a3 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

LEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has successfully defended against an opposition filed against a key patent for its direct-from-whole blood detection method in the European Union. The opposition was filed in May 2023 with the European Patent Office (EPO) by bioMerieux and a strawman representing other undisclosed firm(s) against T2 Biosystems’ granted European Patent No. 3 443 124, which relates to a method for amplifying a target nucleic acid characteristic of a pathogen in a whole blood sample. This patent is part of T2 Biosystems’ intellectual property portfolio surrounding its proprietary direct-from-whole blood pathogen detection method. The Opposition Division of the EPO held a public hearing on September 19, 2024, and ruled such that T2 Biosystems’ strong IP position on the detection of pathogens directly from whole blood was maintained. “This decision further supports the confidence we have in the broad scope conferred by our IP portfolio protecting our proprietary direct-from-whole blood pathogen detection method,” stated John Sperzel, Chairman and CEO of T2 Biosystems. “Given the importance and value of our IP portfolio, we intend to continue to defend against such challenges and remain confident in our leading position, as we advance our technology, commercial platform, and product pipeline.” About T2 BiosystemsT2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology and include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2Biothreat™ Panel. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the T2Lyme™ Panel, and the expended T2Candida Panel to add the detection of Candida auris. For more information, please visit www.t2biosystems.com. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our patent portfolio, the potential of our direct-from-whole blood detection technology and products, statements regarding our patent portfolio, as well as statements that include the words “expect,” “may,” “should,” “anticipate,” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, or SEC, on April 1, 2024, and other filings the Company makes with the SEC from time to time, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release. Investor Contact:Philip Trip Taylor, Gilmartin Groupir@T2Biosystems.com 415-937-5406

DUBLIN--( BUSINESS WIRE )--The "In Vitro Diagnostics (IVD) Quality Controls: Global Market" report has been added to ResearchAndMarkets.com's offering. The global market for In Vitro diagnostics quality controls is expected to grow from $1.5 billion in 2024 and is projected to reach $2.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.8% during the forecast period of 2024 to 2029. This report provides details about the market for in vitro diagnostics quality controls used in checking the in vitro diagnostic devices present in labs, clinics and hospitals. This report will also highlight the current and future market potentiality of in vitro diagnostics quality controls, with a detailed analysis of the competitive environment between companies. Drivers, restraints, opportunities, prevalence or incidence of chronic diseases, and a regulatory scenario assessment will be covered in the current report. The report includes market projections for 2029 and market shares for key players. Based on test type, the market is segmented into immunodiagnostics, clinical chemistry, hematology and hemostasis, molecular diagnostics, microbiology, and others. Based on products and services, the market is categorized into quality control products, data management solutions and quality assurance services. Based on type of manufacturer, the market is segmented into third-party controls and OEM controls. Based on end users, the market is segmented into hospitals, diagnostic laboratories and academic institutions. By geographical region, the market has been segmented into North America, Europe, Asia-Pacific, and Rest of the World. Detailed analyses of major countries such as the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, and GCC countries are covered within the regional segments. For market estimates, data will be provided for 2023 as the base year, with estimates for 2024 and forecast value for 2029. Report Includes 40 data tables and 40 additional tables An overview of the global market for in vitro diagnostics (IVD) quality controls Analysis of global market trends, featuring revenue data for 2021-2023, estimated figures for 2024, and projected CAGRs through 2029 Evaluation of the current market's size and revenue growth prospects, along with a market share analysis by test type, manufacturer, product/services, end user and region Discussion of market drivers and restraints and other dynamics Assessment of the regulatory landscape, including product recalls Analysis of the key companies' market shares, recent M&A activity, acquisitions, joint ventures, partnerships, and patents Company profiles including Abbott, bioMerieux, F. Hoffmann-La Roche Ltd., Siemens Healthineers, and Thermo Fisher Scientific Inc. Company Profiles Abbott BD Biomerieux Bio-Rad Laboratories Inc. Bio-Techne Danaher Corp. F. Hoffmann-La Roche Ltd. Microbiologics Quidelortho Corp. Siemens Heathnieers Ag Sysmex Corp. Thermo Fisher Scientific Inc. Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Chapter 2 Market and Technology Background Introduction Overview Classification of In Vitro Diagnostics Elements Importance of In Vitro Diagnostics Quality Control Regulations Regulation of IVD products in Different countries Chapter 3 Market Dynamics Market Drivers Rise in the Aging Population and Dependency on Frequent Diagnosis Procedures Rising Demand for Third-Party Quality Control Products Rising Incidence of Chronic Disease Cases Strengthening Clinical Laboratories Improving the Quality of Point-of-Care Testing Market Restraints Challenges for Quality Control Product Packaging Increases in Shipping Costs or Service Issues Improper Operation and Maintenance of Laboratory Equipment and Consumables Market Opportunities Rise in Home Care Testing Devices Demand for Point-of-Care (POC) Testing Units Chapter 4 Emerging Technologies and Developments Artificial Intelligence Prioritizing Old IVD Techniques Automating In-Vitro Diagnostic Devices Emerging Trends in In Vitro Diagnostics FDA Approval Rise in Demand for Personalized Medicine Chapter 5 Market Segmentation Analysis Segmentation Breakdown Market Breakdown by Test Type Immunodiagnostics Clinical Chemistry Hematology Molecular Diagnostics Microbiology Other Test Types Market Breakdown by Type of Manufacturer Third-party Controls ODM Controls Market Breakdown by Products and Services Quality Control Products Data Management Solutions Quality Assurance Services Market Breakdown by End User Diagnostic Laboratories Hospitals and Clinics Point-of-Care Centers Research Institutions Other End Users Geographic Breakdown Market Analysis by Region North America Market Size and Forecast U.S. Canada Mexico Europe Market Size and Forecast Germany France U.K. Italy Spain Rest of Europe Asia-Pacific Market Size and Forecast Japan China India Australia and New Zealand Rest of Asia-Pacific Rest of the World Market Size and Forecast Brazil GCC Countries Rest of the World Countries Chapter 6 Competitive Intelligence Introduction Global Analysis of Company Market Ranking Agreements, Collaborations and Partnerships In Vitro Diagnostics Developments and Startups, 2021-2023 Chapter 7 Sustainability Importance of ESG in the In Vitro Diagnostics Industry ESG Practices in the In Vitro Diagnostics Industry Environmental Performance Social Performance Governance Performance Case Studies Publisher Viewpoint Chapter 8 Appendix For more information about this report visit https://www.researchandmarkets.com/r/qp1yas About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.